Articles Articles

Think Fabry, think early treatment to help slow or prevent life-threatening disease progression.^1,2

A post-hoc pooled analysis to evaluate efficacy and safety of insulin glargine 300 U/mL in insulin-naïve people with type 2 diabetes with/ without prior use of glucagon-like peptide-1 receptor agonist therapy.¹

Beneath the skin of patients with AD—type 2 inflammation and the cytokines involved.

A little over a year ago, Sara, 34, received life-changing news: She had been diagnosed with type 1 diabetes. A condition often associated with children and adolescents had suddenly appeared in adulthood. The diagnosis meant adjusting to a new daily routine and undergoing significant mental adaptation. It also brought insights and a deeper understanding of herself. Living in Helsinki, Sara openly shares how her life has changed and how even a little humor can help during challenging times.

When Kris from Oulu heard two years ago that her 16-year-old son Allan had been diagnosed with type 1 diabetes, her world stopped for a moment. Allan, who lives in Rovaniemi with his father, had been symptomatic for a while, but the family hadn't connected the symptoms to a serious illness. The diagnosis was a shock that permanently changed the family's daily life – and Allan's future dream.

The Bright study demonstrated similar efficacy and safety of Toujeo^® (Glargine 300 U/ml) compared to degludec 100 U/ml in type 2 diabetes patients who had not previously received basal insulin¹.

RESTORE-G: Real-world analysis in insulin-naïve adults with T2D on GLP-1 RA ± OAD(s), intensifying their therapy by starting basal insulin and discontinuing GLP-1 RA, or adding basal insulin to ongoing GLP-1 RA, or initiating a FRC product and discontinuing current GLP-1 RA†2